Elsevier

European Urology

Volume 70, Issue 2, August 2016, Pages 227-230
European Urology

Platinum Priority – Brief Correspondence
Editorial by Alexander P. Cole, Firas Abdollah and Quoc-Dien Trinh on pp. 231–232 of this issue
Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?

https://doi.org/10.1016/j.eururo.2016.02.037Get rights and content

Abstract

A better understanding of overall survival among patients with clinically localized prostate cancer (PCa) in the US Veterans Health Administration (VHA) is critical to inform PCa treatment decisions, especially in light of data from the Prostate Intervention Versus Observation Trial (PIVOT). We sought to describe patterns of survival for all patients with clinically localized PCa treated by the VHA. We created an analytic cohort of 35 954 patients with clinically localized PCa diagnosed from 1995 to 2001, approximating the PIVOT inclusion criteria (age of diagnosis ≤75 yr and clinical stage T2 or lower). Mean patient age was 65.9 yr, and median follow-up was 161 mo. Overall, 22.5% of patients were treated with surgery, 16.6% were treated with radiotherapy, and 23.1% were treated with androgen deprivation. Median survival of the entire cohort was 14 yr (25th, 75th percentiles, range: 7.9–20 yr). Among patients who received treatment with curative intent, median survival was 17.9 yr following surgery and 12.9 yr following radiotherapy. One-third of patients died within 10 yr of diagnosis compared with nearly half of the participants in PIVOT. This finding sounds a note of caution when generalizing the mortality data from PIVOT to VHA patients and those in the community.

Patient summary

More than one-third of patients diagnosed with clinically localized prostate cancer treated through the US Veterans Health Administration from 1995 to 2001 died within 10 yr of their diagnosis. Caution should be used when generalizing the estimates of competing mortality data from PIVOT.

References (20)

  • M. Cooperberg et al.

    Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE

    J Urol

    (2003)
  • J.D. Brooks

    Managing localized prostate cancer in the era of prostate-specific antigen screening

    Cancer

    (2013)
  • H.G. Welch et al.

    Overdiagnosis in cancer

    J Nat Cancer Inst

    (2010)
  • T.J. Wilt et al.

    Radical prostatectomy versus observation for localized prostate cancer

    N Engl J Med

    (2012)
  • NCCN clinical practice guidelines in oncology (NCCN Guidelines): prostate cancer, V.1.2011. National Comprehensive...
  • National Center for Veterans Analysis and Statistics. US Department of Veterans Affairs Web site....
  • L.L. Zullig et al.

    Cancer incidence among patients of the U.S. Veterans Affairs Health Care System

    Mil Med

    (2012)
  • A.J. Selim et al.

    The health status of elderly veteran enrollees in the Veterans Health Administration

    J Am Geriatr Soc

    (2004)
  • W.H. Rogers et al.

    Comparing the health status of VA and non-VA ambulatory patients: the veterans’ health and medical outcomes studies

    J Ambul Care Manage

    (2004)
  • L.E. Kazis et al.

    Patient-reported measures of health: the Veterans Health Study

    J Ambul Care Manage

    (2004)
There are more references available in the full text version of this article.

Cited by (18)

  • Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration

    2020, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    Additionally, existing life expectancy estimates may not be used if they are not transportable to a specific population. The poor survival of participants in the PIVOT trial (primarily drawn from the VHA) underscores the need for tools to generate VHA-specific life expectancy estimates [8,9]. We set out to develop life expectancy estimates for Veterans with prostate cancer treated within the VHA, the largest national integrated health care system in the United States.

  • Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer

    2020, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    mCRPC is incurable, with most patients surviving less than 3 years [3,5,11–14]. Prostate cancer is the most commonly diagnosed nonskin cancer among patients cared for and treated in the Veterans Health Administration (VHA) [15]. As the largest integrated healthcare system in the United States, the VHA serves 6-8.5 million Veterans of the US Armed Forces each year at over 1,700 clinics and 152 hospitals, with approximately 13 million primary care visits annually [16].

  • The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration

    2018, Journal of Urology
    Citation Excerpt :

    For each scenario we compared the registry derived cohort to the laboratory derived cohort. We determined the age, gender, race/ethnicity and primary treatment of each patient using administrative data stored in the VHA CDA (Corporate Data Warehouse).6 We calculated the Chamberlain percent positive agreement of the cohorts constructed with registry PSA values compared with laboratory file PSA values.7

View all citing articles on Scopus
View full text